FDA Clears iLet Bionic Pancreas Insulin Delivery System
The FDA has cleared a next-generation insulin pump and software combination that provides greater automation than current "artificial pancreas" systems.
Stay updated with breaking news from Royw Beck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has cleared a next-generation insulin pump and software combination that provides greater automation than current "artificial pancreas" systems.
A meta-analysis of trials examining use of the t:slim X2 insulin pump with Control-IQ technology, results of the study indicate use of the hybrid closed loop technology was associated with improvements in glycemic control, regardless of patient age, race, or previous CGM use.
An artificial pancreas developed at the University of Virginia Center for Diabetes Technology improves blood sugar control for people ages 2 to 72 with type 1 diabetes, according to a new combined analysis of three clinical trials.
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced publication by Diabetes Technology & Therapeutics of a meta-analysis of three randomized... | April 17, 2023
Older children with newly diagnosed type 1 diabetes who received intensive diabetes management with automated insulin delivery had no difference in pancreatic C-peptide levels compared with standard care, according to study data. “Achieving excellent glycemic control soon after diagnosis of type 1 diabetes was unsuccessful in preventing the progressive loss of insulin production by the